

## Journal Pre-proofs

Chronic NOD2 stimulation by MDP confers protection against parthanatos through M2b macrophage polarization in RAW264.7 cells

Florencia C. Mansilla, María C. Miraglia, Silvina S. Maidana, Randazzo Cecilia, Alejandra V. Capozzo

PII: S0171-2985(24)00051-2  
DOI: <https://doi.org/10.1016/j.imbio.2024.152833>  
Reference: IMBIO 152833

To appear in: *Immunobiology*

Received Date: 26 February 2024  
Revised Date: 24 June 2024  
Accepted Date: 28 June 2024

Please cite this article as: F.C. Mansilla, M.C. Miraglia, S.S. Maidana, R. Cecilia, A.V. Capozzo, Chronic NOD2 stimulation by MDP confers protection against parthanatos through M2b macrophage polarization in RAW264.7 cells, *Immunobiology* (2024), doi: <https://doi.org/10.1016/j.imbio.2024.152833>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier GmbH.



## Chronic NOD2 stimulation by MDP confers protection against parthanatos through M2b macrophage polarization in RAW264.7 cells

Florencia C. Mansilla<sup>1\*</sup>; María C. Miraglia<sup>1,2</sup>; Silvina S. Maidana<sup>1,2</sup>; Randazzo Cecilia<sup>1</sup>; Alejandra V. Capozzo<sup>2,3</sup>

<sup>1</sup> Institute of Virology and Technological Innovations, Center for Research in Veterinary and Agronomic Sciences (CICVyA), INTA, Buenos Aires, Argentina

<sup>2</sup> National Council for Scientific and Technical Research (CONICET)

<sup>3</sup> Center for Advanced Studies in Human Sciences and Health (CAECIHS), Interamerican Open University (UAI), Buenos Aires, Argentina

\*Corresponding author: manslla.florencia@inta.gob.ar Institute of Virology and Technological Innovations, Center for Research in Veterinary and Agronomic Sciences (CICVyA), INTA-National Council for Technical Research (CONICET), N. Repetto y De Los Reseros s/n (1686), Hurlingham 1686, Buenos Aires, Argentina

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Abstract

1 Innate immune cells show enhanced responsiveness to secondary challenges after an  
2 initial non-related stimulation (Trained Innate Immunity, TII). Acute NOD2 activation by  
3 Muramyl-Dipeptide (MDP) promotes TII inducing the secretion of pro-inflammatory  
4 mediators, while a sustained MDP-stimulation down-regulates the inflammatory  
5 response, restoring tolerance. Here we characterized *in-vitro* the response of murine  
6 macrophages to lipopolysaccharide (LPS) challenge under NOD2-chronic stimulation.  
7 RAW264.7 cells were trained with MDP (1µg/ml, 48h) and challenged with LPS (5µg/ml,  
8 24h). Trained cells formed multinucleated giant cells with increased phagocytosis rates  
9 compared to untrained/challenged cells. They showed a reduced mitochondrial activity  
10 and a switch to aerobic glycolysis. TNF-α, ROS and NO were upregulated in both trained  
11 and untrained cultures (MDP+, MDP- cells, p>0.05); while IL-10, IL-6 IL-12 and MHCII  
12 were upregulated only in trained cells after LPS challenge (MDP+LPS+, p<0.05). A slight  
13 upregulation in the expression of B7.2 was also observed in this group, although

14 differences were not statistically significant. MDP-training induced resistance to LPS  
15 challenge ( $p < 0.01$ ). The relative expression of PARP-1 was downregulated after the LPS  
16 challenge, which may contribute to the regulatory milieu and to the innate memory  
17 mechanisms exhibited by MDP-trained cells. Our results demonstrate that a sustained  
18 MDP-training polarizes murine macrophages towards a M2b profile, inhibiting  
19 parthanatos. These results may impact on the development of strategies to  
20 immunomodulate processes in which inflammation should be controlled.

21 **Keywords:** M2b macrophages, muramyl-dipeptide, NOD2, LPS resistance,  
22 PARP-1

23

## 24 1. Introduction

25 Emerging studies have demonstrated that innate immune cells have primitive immune  
26 memory mechanisms referred to as *Trained Innate Immunity* (Quintin et al., 2014),  
27 adapting non-specifically after a transient stimulation through metabolic and epigenetic  
28 modifications thus remaining with enhanced responsiveness to secondary challenges with  
29 a non-related stimuli (Netea et al., 2020, 2011). Even though trained innate immunity can  
30 be induced in all immune cell types and in some non-immune cell types, this concept was  
31 first established in monocyte-derived macrophages, inducing phenotypical polarization to  
32 mount specific functional programs (Hamada et al., 2019). During this process,  
33 macrophages adopt different functional characteristics in response to specific  
34 environmental contexts. This results in the differentiation of macrophages into two main  
35 types: classically activated (M1), induced by stimuli that can be structural units of  
36 different pathogens (such as LPS) or pro-inflammatory molecules secreted by other  
37 immune cells (IFN- $\gamma$ ), producing proinflammatory cytokines, nitric oxide, and reactive  
38 oxygen intermediates to combat pathogens; and alternatively activated (M2)  
39 macrophages, induced by cytokines such as IL-4, IL-10, or IL-13 and involved in wound  
40 healing, tissue repair, regulatory response and extracellular matrix formation. M2  
41 macrophages are further differentiated into M2a, M2b, M2c, and M2d subtypes, each  
42 distinguished by unique cell surface markers, cytokines released and biological roles  
43 (Gordon, 2003; Van Genderachter et al., 2006; Wang et al., 2019).

44 Muramyl dipeptide (MDP) is the minimal structural unit of bacterial peptidoglycan,  
45 which consists of N-acetylglycosamine and N-acetylmuramic acid disaccharide chains  
46 linking the lactyl group of one N-acetylmuramic acid to the other, typically in L-alanine  
47 D-glutamine dipeptides (Ogawa et al., 2011). It is the major structural element of the cell  
48 walls of most bacteria that can elicit an immune response through the activation of NF-  
49  $\kappa$ B and MAPK signaling pathways resulting in the production of proinflammatory  
50 cytokines. In this context, the pro-inflammatory effect of muramyl dipeptide (MDP) is  
51 prototypical. MDP synergistically enhance the secretion of LPS-induced  
52 proinflammatory mediators after binding to NOD2 (Girardin et al., 2003), which is  
53 associated to the activation of neutrophils, monocytes, macrophages and lymphocytes  
54 (Guryanova and Khaitov, 2021). Interestingly, MDP can also regulate intracellular  
55 processes, triggering anti-inflammatory and regulatory responses to down-regulate  
56 inflammation, ensuring tolerance to microbiome and preventing septic shock  
57 (Guryanova, 2022). It was suggested that while acute NOD2 activation by MDP signals  
58 through NF $\kappa$ B and MAPK pathways, a sustained stimulation may promote NOD2  
59 degradation, thus restoring both self- and cross-tolerizing effects (Guryanova and

60 Khaitov, 2021). The absence of tolerogenic responses may lead macrophages to  
61 parthanatos, an overproduction-related cell death program (Robinson et al., 2019) which  
62 relies on the hyper-activation of Poly [ADP-ribose] polymerase 1 (PARP-1) mediated by  
63 oxidative and nitrosative stress (Andrabi et al., 2008; David et al., 2009). Hence, the  
64 restoration of homeostasis after inflammation is paramount.

65 Peripheral monocytes and macrophages that enter mucosal sites are continuously exposed  
66 to both local and systemic effects of MDP present in the bloodstream because of the  
67 microbiome breakdown (Guryanova, 2022; Guryanova and Khaitov, 2021; Huang et al.,  
68 2019). However, the potential protective role of MDP-mediated chronic NOD2  
69 stimulation considering its tolerogenic effect is not totally understood, as studies have  
70 mainly focused on functions after acute, rather than chronic NOD2 stimulation  
71 (Guryanova and Khaitov, 2021). Considering this, in this study we aimed to characterize  
72 *in vitro* the immune response of murine macrophages to an experimental LPS challenge  
73 in the context of chronic inflammation induced by a sustained stimulation of NOD2 using  
74 MDP.

75

## 76 **2. Materials and Methods**

### 77 **2.1 Cells and treatments**

78 RAW264.7 cells from the American Type Cell Collection (ATCC®) were  
79 cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco®, Thermo  
80 Fisher, DE, USA) supplemented with fetal bovine serum (FBS) 10% (v/v), Hepes  
81 (10 mM), glutamine (2 mM) and 1% (v/v) of Gibco™ Antibiotic-antimycotic  
82 solution (100X, Gibco), containing penicillin 100 U/ml, streptomycin 100 µg/ml  
83 and Amphotericin B 0.25 µg/ml. Experiments were performed using the same  
84 batch of each reagent and cells were maintained no longer than fifteen passages  
85 to preserve culture identity (Taciak et al., 2018). Cells were gently detached with  
86 a scrapper and counted. A final volume 0.2 or 1 ml/well of supplemented DMEM  
87 containing  $2 \times 10^4$  or  $2 \times 10^5$  cells was seeded in 96 or 12 well plates, respectively.  
88 In each experiment, an aliquot containing  $5 \times 10^4$  cells was stained with a  
89 fluorescent probe as described below (section 2.4) to verify their viability (data  
90 not shown). After an ON resting period, cells were trained with 1 µg/ml of MDP  
91 (referred to as MDP+ cells, InvivoGen, CA, USA) and incubated for 48h at 37°C  
92 and 5% CO<sub>2</sub> in complete DMEM supplemented with 2% FBS. Then supernatants  
93 were removed and lipopolysaccharide from *Escherichia coli* O127:B8 (LPS, 5  
94 µg/ml, Sigma Aldrich, MO, USA) in complete DMEM with 2% FBS was added  
95 (referred to as MDP+LPS+ cells). After 24h supernatants were collected and  
96 stored at -80°C until processing and cells were detached (if necessary) and  
97 processed. In each experiment, cells that were LPS challenged in the absence of  
98 training with MDP (MDP-LPS+) and a control group that was neither trained with  
99 MDP nor challenged (MDP-LPS-) were included.

### 100 **2.2 Morphological and functional modifications induced by MDP**

101 The induction of morphological modifications by MDP training was verified by  
102 Papanicolaou staining using a commercial kit (Tincion15, Biopur, Santa Fe,  
103 Argentina) following the manufacturer's protocol. Briefly, sterile glass culture  
104 slides (Sigma Aldrich) were placed on 12 well plates, then  $2 \times 10^5$  cells in 1 ml of  
105 supplemented DMEM (10% FBS) were seeded in each well and incubated for 48h  
106 with MDP (1µg/ml) at 37°C with CO<sub>2</sub> 5%. Then supernatants were discarded,  
107 glasses were washed with PBS 1x and carefully detached using a 25g needle. Each

108 glass was then sequentially immersed for 5 seconds in each one of the solutions  
109 provided by the manufacturer (fixative solution, solution 1 containing xanthinic  
110 dyes and solution 2 containing thiazine dyes). Glasses were then washed with  
111 running water and air dried, before being observed under optical microscope.  
112 Giant multinucleated cells were quantified in five randomly obtained pictures of  
113 each treatment using ImageJ (Hartig, 2013).

114 The phagocytic ability of the trained cells in response to LPS challenge  
115 (MDP+LPS+) was measured by neutral red uptake following manufacturer's  
116 instructions. Supernatants were removed and preserved at -80°C and 100 µl of  
117 neutral red solution (0.075% w/v) in PBS 1x, Sigma Aldrich) was added to each  
118 well using 96-well plates. Plates were incubated for 2h at 37°C, washed twice with  
119 PBS 1x (250 µl/well) and incubated with 150 µl/well of a destaining solution  
120 (ethanol: H<sub>2</sub>O: acetic acid, 50:49:1) at 37°C for 10 min with constant agitation.  
121 OD<sub>540</sub> was determined by spectrophotometry.

122 The XTT reducing activity was assessed using a commercial kit (TACS® XTT  
123 Cell Proliferation Assay Kit, BioTechne, CA, USA) according to manufacturer's  
124 instructions. Briefly, 50 µl/well of working solution (xtt activator: xtt reagent,  
125 1:50) were added to each well from 96-well plates. Cells were incubated for 2h at  
126 37°C and 5% CO<sub>2</sub> and OD<sub>490</sub> was determined by spectrophotometry.

127 The glucose intake was assessed enzymatically using a commercial reagent  
128 containing glucose oxidase, peroxidase and 4-aminophenazone (Glucose,  
129 Biosystems S.A.S., Colombia). Supernatants previously collected (10 µl) were  
130 incubated with 1ml of the commercial reagent at 37°C for 5 min. OD<sub>505</sub> was  
131 determined using a spectrophotometer.

### 132 **2.3 Cytokine production and expression of MHCII and B7.2**

133 The production of TNF-α, IL-10, IL-12 and IL-6 was determined by ELISA using  
134 commercial kits (BD OptEIA™ ELISA sets, BD, NJ, USA). Briefly, ELISA  
135 plates were incubated with capture antibody ON at 4°C. Then plates were washed  
136 with PBS-Tween 0.05% (3x, 250 µl/well), blocked (PSB-FBS 10%, 200 µl/well,  
137 1h at room temperature) and undiluted supernatants were seeded (100 µl/well) and  
138 incubated for 2h at room temperature. After this incubation step, plates were  
139 washed with PBS-Tween 0.05% (5x, 250 µl/well) and both the detector antibody  
140 and the secondary antibody conjugated to peroxidase were added together,  
141 following manufacturer's instructions (diluted 1:250, 100 µl/well, 1h at room  
142 temperature). Plates were washed again (7x, 250 µl/well) and a substrate solution  
143 containing TMB was added (100 µl/well, BD). After an incubation of 30 min at  
144 room temperature in dark, stop solution (H<sub>2</sub>SO<sub>4</sub> 2 N, 50 µl/well) was added and  
145 OD<sub>450</sub> was determined. Results were compared to a standard curve.

146 Expression of MCHII and B7.2 on cell membrane were detected using FITC-  
147 conjugated anti-Mouse I-A[d] and anti-Mouse CD86 antibodies (BD). Briefly,  
148 1x10<sup>6</sup> cells were resuspended in 20 µl of staining buffer (PBS-FBS 2%) and 0.5  
149 µg of each antibody was added on separated tubes. Cells were incubated for 15  
150 min at 4°C, washed twice with PBS 1x (5 min at 800g), and fixed with 100 µl of  
151 paraformaldehyde (PFA) 0.2% (w/v). Cells were analyzed by flow cytometry  
152 using a FACSCalibur™ flow cytometer (Becton Dickinson Immunocytometry  
153 Systems™, San Diego, USA). Isotype-matched control antibodies were used, and  
154 a gate was defined in the analysis to exclude non-viable cells and debris. SSC vs  
155 FL1 data were acquired. Results were analyzed using FlowJo\_V10 software (BD)  
156 and dot plots were obtained showing the percentage of positive events.

### 157 **2.4 Determination of Reactive Species and membrane integrity**

158 The production of Nitric Oxide (NO) was quantified spectrophotometrically using  
159 Griess Reagent Kit (Biotium, CA, USA) in the supernatant of trained or untrained  
160 challenged cells (MDP+LPS+ or MDP-LPS+, respectively). Samples (150  $\mu$ l)  
161 were incubated with 20  $\mu$ l of the commercial reagent and 130  $\mu$ l of distilled water  
162 for 30 min at room temperature and OD<sub>548</sub> was determined using a  
163 spectrophotometer. Results were compared to a standard curve.

164 Total Reactive Oxygen Species (ROS) were measured using a commercial kit  
165 based on intracellular staining with DCFDA/H2DCFDA (Total Reactive Oxygen  
166 Species (ROS) Assay Kit 520 nm, Thermo Fisher). Briefly,  $1 \times 10^6$  cells were  
167 resuspended in 100  $\mu$ l of a solution containing DCFDA/H2DCFDA diluted 1:500  
168 in PBS 1x. Cells were incubated at 37°C for 1h, washed (2x) in PBS 1x and fixed  
169 with PFA 0.2% (w/v).

170 Viability was determined by assessing membrane integrity with a commercial  
171 probe (LIVE/DEAD Viability/Cytotoxicity Kit, Thermo Fisher), which was  
172 diluted 1:1000 in PBS 1x.  $1 \times 10^6$  cells were resuspended in 500  $\mu$ l of this solution  
173 and incubated for 15 min at 4°C. Cells were then washed (2x in 1ml of PBS), fixed  
174 with 100  $\mu$ l of PFA 0.2% (w/v) and analyzed by flow cytometry. Cells were  
175 identified by their forward scatter properties and FSC vs FL4 were analyzed and  
176 the subpopulation of cells with lower intensity were gated (“LIVE”). Results were  
177 analyzed using FlowJo\_V10 software (BD) and dot plot for FSC vs FL4 were  
178 obtained, indicating the percentage of live cells (%).

## 179 **2.5 Relative expression levels of PARP-1**

180 RNA from trained or untrained challenged cells (MDP+LPS+ or MDP-LPS+) was  
181 extracted following a standard protocol using Biozol reagent (Pb-L, Buenos Aires,  
182 Argentina). Unchallenged cells, with or without previous MDP training  
183 (MDP+LPS- and MDP-LPS-, respectively) were included as controls. RNA  
184 samples were digested with DNase (1  $\mu$ g/each with 1U of RQ1, Promega, WI,  
185 USA) for 30 min at 37°C. Then RQ1 stop solution was added and incubated for 10  
186 min at 65°C for enzyme inactivation. The integrity of extracted RNA samples was  
187 verified by electrophoresis. Samples were incubated with M-MLV (200 U/sample,  
188 Promega) for 1h at 42°C for reverse transcription followed by 10 min at 94°C for  
189 enzyme inactivation (Promega). RNA purity and quantity was determined using a  
190 spectrophotometer (260<sub>nm</sub>/280<sub>nm</sub>).

191 The relative expression of PARP-1 was assessed by Real Time PCR using  
192 previously described primers (Fw: GGAGCTGCTCATCTTCAACC; Rv:  
193 GCAGTGACATCCCCAGTACA; Regdon et al., 2019). B-actin was used as  
194 reference gen (Fw: 5'-GAGACCTTCAACACCCCAGC-3'; Rv: 5'-  
195 ATGTCACGCACGATTTCCC-3'). Amplifications were performed using Mix  
196 qPCR SYBR/ROX (Pb-L) and following a standard reaction (95°C for 10 min and  
197 40 cycles at 95°C for 30s, 60°C for 30s, 72°C for 30s for termination). Melting  
198 curve analysis was conducted after each cycle (StepOne, Applied Biosystems,  
199 Thermo Fisher). The delta-delta CT method was used to determine the relative  
200 expression of PARP-1, as previously described (Livak and Schmittgen, 2001).  
201 Briefly, the average Ct value for PARP-1 and  $\beta$ -Actin and the  $\Delta$ Ct values in each  
202 experimental (MDP+LPS+; MDP+LPS- or MDP-LPS+) and control condition  
203 (MDP-LPS-) was calculated. Then, the difference in gene expression between  
204 experimental and control samples was obtained ( $\Delta\Delta$ Ct) subtracting the  $\Delta$ Ct value  
205 of the control sample from the  $\Delta$ Ct value of the experimental samples. This value  
206 was then used to calculate the fold change in gene expression between the samples  
207 ( $2^{-\Delta\Delta Ct}$ ).

208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221


## 2.6 Statistical analysis

All determinations were carried out in three independent experiments with three replicates each. Comparisons between groups were assessed by One Way ANOVA followed by Tukey Test to evaluate significant differences between groups (95% CI). Graphpad Prism 9.0 software was used.

## 3 Results

### 3.1 Metabolic and morphologic effects of chronic NOD2 stimulation

The optimal concentration of LPS was experimentally determined. Increased phagocytosis activity was observed in cells challenged either with 5 or 10  $\mu\text{g/ml}$  of LPS, while no differences were found in cells challenged with 1  $\mu\text{g/ml}$  of LPS compared to unchallenged cells (Fig. 1a,  $p < 0.05$ ). The XTT reduction activity was not affected by LPS challenge within the range evaluated (1-10  $\mu\text{g/ml}$ ; Fig. 1b,  $p > 0.05$ ), compared with unchallenged cells.




222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247

**Fig. 1. Set up of experimental LPS challenge.** RAW264.7 cells were experimentally challenged with increasing amounts of LPS (0-10  $\mu\text{g/ml}$ ) and incubated for 24h at 37°C and 5%  $\text{CO}_2$ . The phagocytic (a) and XTT reduction activity (b) of LPS challenged cells was assessed spectrophotometrically. Results from three independent experiments with three replicates each are depicted. Comparisons between groups were determined by One-Way ANOVA followed by Tukey post-test. Significant differences are depicted ( $p < 0.05$ )

The presence of multinucleated giant cells, indicative of chronic inflammation, was verified by Papanicolaou staining (Fig. 2a and 2b) in MDP-trained cells (MDP+, 48h). After counting giant cells from 5 randomly taken photographs, an average value of 20 cells was observed in response to MDP training. This increase was statistically significant compared to untrained cells (MDP-), in which an average of 2.8 giant cells were counted ( $p < 0.001$ ).

RAW264.7 cells (MDP+ or MDP-) were then experimentally challenged with high doses of LPS (5  $\mu\text{g/ml}$ ) for 24h, as previously standardized.

The phagocytic activity of MDP+LPS+ cells was determined assessing neutral red intake levels. No differences were observed between MDP+LPS+ and MDP-LPS+ cells. However, our results showed an upregulation of phagocytosis induced by LPS challenge in both trained and untrained cells (MDP+LPS+ and MDP-LPS+, respectively; Fig. 2c) with statistically significant differences compared to MDP-LPS- cells ( $p < 0.05$ ). A reduced mitochondrial activity, inferred by a decreased XTT reduction activity ( $p < 0.05$ ), and higher consumption rates of glucose were also observed after LPS experimental challenge but only in MDP-trained cells (MDP+LPS+, Fig. 2d and 2e, respectively).




248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266

**Fig. 2. Metabolic and morphologic effects of chronic NOD2 stimulation.** The effect of a sustained MDP training on RAW264.7 cells was determined. a) Representative images of untrained (MDP-LPS-, left panel) vs MDP-trained (MDP+LPS-, right panel) cells are shown under 20x and 40x objective lens. Papanicolaou-stained giant multinucleated cells are depicted (black arrows). b) Giant multinucleated cells were quantified (ImageJ, NIH). Five pictures were randomly obtained from MDP-trained (MDP+LPS-) or untrained cells (MDP-LPS-) and the number of giant multinucleated cells under each condition was determined. Phagocytosis rates inferred from neutral red intake and XTT reduction activity (c and d, respectively) of MDP trained or untrained cells were determined after LPS experimental challenge (MDP+LPS+ and MDP-LPS-, respectively). Untrained/unchallenged cells (MDP-LPS-) were left as control cells. e) The glucose consumption under each experimental condition was also determined in an enzymatic assay. Results from three independent experiments with three replicates each are shown. Differences between groups were determined by One Way ANOVA followed by Tukey Test. Mean values  $\pm$  SD and significance levels are depicted.

### 3.2 Cytokines production and expression of activation markers

267  
268  
269  
270  
271  
272  
273

The expression of different cytokines in the supernatant of trained cells that were experimentally challenged with LPS (MDP+LPS+) was determined by ELISA. TNF- $\alpha$  levels were upregulated by LPS without significant differences between MDP-trained (MDP+LPS+) or untrained cells (MDP-LPS+, Fig. 3a). Increased levels of IL-10, IL-6 and IL-12 were also detected after LPS challenge only in MDP-trained cells (MDP+LPS+, Fig. 3b, 3c and 3d, respectively;  $p < 0.05$ ).



274  
275  
276  
277  
278  
279  
280


**Fig 3. Cytokine production.** The production of TNF- $\alpha$  (a), IL-10 (b), IL-12 (c) and IL-6 (d) was quantified in the supernatant of trained and untrained RAW264.7 cells after LPS challenge (MDP+LPS+ and MDP-LPS+, respectively) by ELISA using a commercial kit. Untrained/unchallenged cells (MDP-LPS-) were left as control. Statistical differences between treatments determined by One Way ANOVA followed by Tukey Test and the level of significance are depicted.



281 Results from three independent experiments with three replicates each are shown.  
 282 Mean values  $\pm$  SD are plotted.

283

284 The expression of MHCII and B7.2 on trained cells and its modulation in response  
 285 to LPS challenge by flow cytometry was assessed. Our results showed a strong  
 286 upregulation of MHCII induced by MDP sustained training after LPS challenge  
 287 (MDP+LPS+ cells), with significant differences compared to the other  
 288 experimental groups (MDP-LPS+; MDP+LPS- and MDP-LPS- cells; Fig 4a and  
 289 4b;  $p < 0.05$ ). Increased levels of B7.2 was also observed in MDP+LPS+ cells,  
 290 although differences were not statistically significant (Fig. 4c and 4d;  $p < 0.05$ ).



291

292

293 **Fig 4. Upregulation of MHCII and B7.2.** Trained and untrained RAW264.7  
 294 cells were stained with specific surface markers to determine the expression of  
 295 MHCII and B7.2 after LPS experimental challenge (MDP+LPS+ or MDP-LPS+)  
 296 by flow cytometry. Schematic representation of the modulation of the expression  
 297 of MHCII and B7.2 under different experimental conditions (a and c,  
 298 respectively). The percentage of cells expressing MHCII (b) and B7.2 (c)  
 299 on their surface (%) is depicted. Trained and untrained/unchallenged cells (MDP+LPS-  
 300 and MDP-LPS-, respectively) were left as control. Statistical differences  
 301 determined by One-Way ANOVA followed by Tukey Test and the level of  
 302 significance between groups are shown. Results from three independent  
 303 experiments with three replicates each are depicted. Mean values  $\pm$  SD are plotted.

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323


324

325

326

327

The production of ROS and NO was quantified in trained cells after LPS challenge using a fluorescent stain or Griess Reaction, respectively. LPS challenge induced high levels of both ROS and NO, without differences between trained (MDP+LPS+) and untrained cells (MDP-LPS+, Fig. 5a and b).



308

309

310

311

312

313

314

315

316


**Fig 5. Production of oxygen and nitrogen reactive species.** The production of ROS (a) and nitric oxide (b) was determined using DCFDA/H2DCFDA staining

311 and Griess Reaction, respectively, in trained and un-trained cells after LPS  
 312 challenge (MDP+LPS+ or MDP-LPS+). Unchallenged cells (both MDP+LPS-  
 313 and MDP-LPS-) were left as controls. Statistic differences assessed by One-Way  
 314 ANOVA followed by Tukey Test and the level of significance between groups  
 315 are shown. Results from three independent experiments with three replicates each  
 316 are shown. Mean values  $\pm$  SD are plotted.

317

### 318 3.3 Resistance to LPS challenge

319 The viability of MDP-trained cells after LPS challenge (MDP+LPS+) was  
 320 inferred assessing membrane integrity using a fluorescent probe. The percentage  
 321 of live cells was determined under each experimental condition by flow  
 322 cytometry. An increase in the number of live cells was observed in MDP-trained  
 323 cells in response to LPS (MDP+LPS+), compared to untrained challenged cells  
 324 (MDP-LPS+); indicating a protective effect induced by MDP training associated  
 325 with greater resistance to the experimental challenge. (Fig. 6a and 6b,  $p < 0.001$ ).




326 **Fig 6. Resistance to LPS challenge.** MDP trained and untrained RAW264.7 cells  
 327 were experimentally challenged with LPS (MDP+LPS+ and MDP-LPS+,  
 328 respectively). Trained/unchallenged (MDP+LPS-) and untrained/unchallenged  
 329 cells (MDP-LPS-) were left as controls. a) Schematic representation of the  
 330 survival rate under each experimental condition, according to membrane integrity  
 331 assessment by flow cytometry. b) Survival rate of cells under different  
 332 experimental treatments after LPS challenge. Results were obtained from three  
 333 independent experiments with three replicates each. Mean values  $\pm$  SD are plotted.

334

### 335 3.4 Relative expression of PARP-1

336 To explore possible mechanisms involved in the LPS resistance observed, the  
 337 relative expression of PARP-1, an early responder in the DNA damage response  
 338 whose inhibition induces trained innate immunity and protects from endotoxemia,  
 339 was determined by real time PCR. The integrity of the extracted RNAs and  
 340 absence of genomic DNA after DNase digestion was verified by electrophoresis  
 341 in an agarose gel (data not shown). Our results suggest that PARP-1 is  
 342 significantly downregulated after LPS experimental challenge in both  
 343 MDP+LPS+ and MDP-LPS+ ( $p < 0.05$ ) and that this downregulation is  
 344 significantly deepened when challenged cells were previously trained with MDP  
 345 (MDP+LPS+ cells, Fig. 7,  $p < 0.001$ ). An increase in the expression levels of  
 346 PARP-1 induced by MDP treatment prior to the LPS challenge (MDP+LPS-) was  
 347 also observed. This suggests a central role of PARP-1 in the MDP-mediated  
 348 resistance to LPS challenge.



349

350 **Fig 7. Relative PARP-1 expression.** The relative PARP-1 expression was assessed by  
 351 real time PCR in both trained and untrained RAW264.7 cells after LPS challenge  
 352 (MDP+LPS+ and MDP-LPS+, respectively) according to the  $2^{-\Delta\Delta C_t}$  method.  
 353 Untrained/challenged (MDP-LPS+) and untrained/unchallenged (MDP-LPS-) cells were  
 354 left as controls. Comparisons between groups were determined by One Way ANOVA  
 355 followed by Tukey Post-test. Average values from three independent experiments with  
 356 three replicates each are shown. Mean values  $\pm$  SD are plotted.

357

#### 358 4 Discussion

359 Trained Innate Immune response plays a key emerging role in the control of several  
 360 diseases. However, it is now known that wrong or excessive trained innate immunity  
 361 induction can cause an undesired effect, leading to unfavorable outcomes (Mishra et al.,  
 362 2022; Netea et al., 2020). A single compound can exhibit great variation on its stimulating  
 363 capacity depending on the source from which it is obtained, mass and schedule of  
 364 administration (Byrne et al., 2021). Thus, trained innate immunity response and the  
 365 concomitant macrophage polarization constitute a versatile target to control a broad  
 366 spectrum of immunologic scenarios, including not only infectious, metabolic and  
 367 inflammatory diseases, but also those in which anti-inflammatory or tolerogenic  
 368 responses are needed to guarantee the restoration of homeostasis (Arts et al., 2018;  
 369 Cárdenas-Tueme et al., 2020; Leentjens et al., 2018). Considering the pivotal role of  
 370 MDPs in the modulation of different aspects of the immune response, we developed a  
 371 model in which the effect of chronic NOD2 stimulation and its response against LPS  
 372 challenge could be characterized *in vitro* using RAW264.7 cells. Although the use of cell  
 373 lines has certain limitations, it is generally accepted that these cells are comparable to  
 374 primary cultures of macrophages in terms of their ability to reproduce phagocytosis and  
 375 immunomodulatory effects of different medications or immunomodulators (Baek et al.,  
 376 2020; Elisia et al., 2018; Wei et al., 2022).

377 Our results demonstrate a strong macrophage polarization towards an M2b profile. These  
 378 macrophages are involved in the resolution of inflammation through anti-inflammatory  
 379 and/or regulatory functions, which can result in either protective or pathogenic outcomes  
 380 in different disorders. They were first characterized in 2002 and, since then, different  
 381 markers have been proposed (Anderson and Mosser, 2002; Martinez et al., 2008).  
 382 Recently, Wang et al defined this phenotype as IL-10+, IL-12-, IL-6+, TNF- $\alpha$ +,  
 383 CD11b+, MHCII+ cells (Wang et al., 2019). Our results evidenced an upregulation of  
 384 both TNF- $\alpha$  and IL-10, reported as the main markers for M2b phenotype (Wang et al.,

385 2019). It was described that later phases of macrophage responses to TNF- $\alpha$  upregulate  
386 IL-10 production which induces cross-tolerance to subsequent TLR stimulation, thereby  
387 suppressing excessive pro-inflammatory cytokine production (Huynh et al., 2016; Park et  
388 al., 2011). M2b macrophages also inhibit conversion from quiescent M0 to M1,  
389 promoting tolerance (Wang et al., 2019). Thus, the induction of this profile by a chronic  
390 stimulation of NOD2 mediated by MDP, which is present in most bacteria, may have  
391 evolve as a protective strategy to avoid the induction of antimicrobial response.

392 The observed upregulation of both MHCII as well as the detection of high levels of IL-  
393 6 and low levels of IL-12, which is negatively regulated by IL-10 (Ma et al., 2015), were  
394 also indicative of an M2b profile. The expression of B7.2 was also upregulated by MDP,  
395 but differences were not statistically significant (Mantovani et al., 2004; Martinez et al.,  
396 2008; Yu et al., 2016).

397 The increased phagocytosis rates and decreased mitochondrial activity observed in  
398 MDP+LPS+ cells suggest a metabolic switch to aerobic glycolysis which was further  
399 supported by increased levels of glucose intake in those cells. This is usually induced by  
400 the free radicals produced under hypoxic conditions and contributes to macrophage  
401 activation (Kelly and O'Neill, 2015; Liu et al., 2012; Rodríguez-Prados et al., 2010; Wang  
402 et al., 2021). The presence of multinucleated giant cells, hallmark of chronic  
403 inflammation, was also evidenced after MDP training, although less is known about both  
404 their biological and functional activities in the context of macrophage polarization  
405 (Ahmadzadeh et al., 2022).

406 The LPS-induced production of both NO and ROS in RAW264.7 cells was previously  
407 reported, although different LPS concentrations were used in those studies (Aldridge et  
408 al., 2008; Asgharpour et al., 2019; Baek et al., 2020). In our model, no differences in NO  
409 or ROS levels between trained and untrained challenged cells (MDP+LPS+ and MDP-  
410 LPS+, respectively) were detected. Reactive species mediate different cellular processes  
411 and are one of the main actors of macrophages' microbicide activity (Aldridge et al.,  
412 2008). However, it is known that an excessive or prolonged production of RNS/ROS is  
413 associated to tissue damage (Guzik et al., 2003; MacMicking et al., 1997), which is  
414 detrimental or even lethal to the cells, unless regulatory mechanisms are triggered  
415 (Regdon et al., 2019).

416 Considering these results, we aimed to determine the survival rate of cells exposed under  
417 high levels of nitrosative and oxidative stress. Despite most of the untrained cells (MDP-  
418 LPS+) faced death after challenge, a remarkable level of LPS resistance was observed  
419 induced by MDP training (MDP+LPS+). Parthanatos was previously verified in  
420 RAW264.7 cells and it was also demonstrated that PARP-1 inhibitors significantly  
421 reduced LPS-mediated cell death in mice both *in vivo* and in RAW264.7 cells, verifying  
422 the cross-talk between parthanatos and PARP-1 in endotoxemia (Xue et al., 2021). It was  
423 also reported that in M1 macrophages, sustained oxidative stress can lead to parthanatos,  
424 which is interestingly mitigated by LPS, suppressing PARP-1, boosting antioxidant  
425 proteins, and switching from mitochondrial respiration to aerobic glycolysis for energy  
426 production (Regdon et al., 2019). However, macrophages' plasticity and particularly the  
427 role of M2b macrophages in parthanatos, remain unexplored. MDP treatment induced an  
428 upregulation of PARP-1 relative expression in unchallenged cells (MDP+LPS-).  
429 However, in response to LPS challenge both MDP+ and MDP- cells expressed  
430 significantly lower levels of PARP-1 than unchallenged cells (MDP+LPS- and MDP-  
431 LPS-). MDP training intensified this downregulation (in MDP+LPS cells), with

432 significant differences compared to MDP-LPS-. This may contribute to the regulatory  
433 milieu and to the innate memory mechanisms exhibited by MDP-trained cells.

434 PARP-1 has a complex and apparently promiscuous role in both pro-inflammatory  
435 processes downstream NfκB and DNA damage responses repairing DNA lesions induced  
436 by oxidative stress. The impact of PARP-1 suppression on cellular response to cytotoxic  
437 stimuli may depend on the severity of cellular stress. Given its dual function in regulating  
438 cell death, it is believed that under moderate DNA damage, its inhibition may enhance  
439 cellular susceptibility to parthanatos by disrupting DNA repair mechanisms. On the other  
440 hand, under extreme stress conditions with irreparable DNA breakage, PARP-1  
441 downregulation seems to protect cells from necrosis (Regdon et al., 2019). Furthermore,  
442 PARP-1 inhibition induces trained innate mechanisms (Kim et al., 2020; Swindall et al.,  
443 2013), as oxidized DNA fragments translocate from the nucleus to the cytosol activating  
444 TLR9 signaling pathway (Liu et al., 2015). Hence, MDP-induced PARP-1  
445 downregulation after LPS challenge and the subsequent impairment of the DNA Damage  
446 response may contribute to trained innate immune mechanisms triggered by NOD2,  
447 probably in collaboration with TLR9. Even though the synergistic activation of NODs  
448 and TLRs was already suggested by different authors (Pashenkov et al., 2019; Underhill,  
449 2007), this should be further studied in this context.

450 Our results showed that chronic NOD2 stimulation mediated by MDP induces a  
451 regulatory effect, promoting an M2b phenotype which confers protection against  
452 parthanatos in RAW264.7 cells after a secondary LPS-challenge. Therefore, unraveling  
453 trained innate immunity mechanisms and macrophage polarization triggered by pattern  
454 recognition receptor (PRR) stimulation in different contexts emerges a powerful tool to  
455 develop high-potential strategies aimed at modulating immunological disorders.

456

## 457 **5 Bibliography**

458 Ahmadzadeh, K., Vanoppen, M., Rose, C.D., Matthys, P., Wouters, C.H., 2022.  
459 Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities,  
460 and Mechanism of Formation. *Front. cell Dev. Biol.* 10.  
461 <https://doi.org/10.3389/FCELL.2022.873226>

462 Aldridge, C., Razzak, A., Babcock, T.A., Helton, W.S., Espat, N.J., 2008.  
463 Lipopolysaccharide-stimulated RAW 264.7 macrophage inducible nitric oxide  
464 synthase and nitric oxide production is decreased by an omega-3 fatty acid lipid  
465 emulsion. *J. Surg. Res.* 149, 296–302. <https://doi.org/10.1016/J.JSS.2007.12.758>

466 Anderson, C.F., Mosser, D.M., 2002. A novel phenotype for an activated macrophage:  
467 the type 2 activated macrophage. *J. Leukoc. Biol.* 72, 101–106.  
468 <https://doi.org/10.1189/JLB.72.1.101>

469 Andrabi, S.A., Dawson, T.M., Dawson, V.L., 2008. Mitochondrial and nuclear cross talk  
470 in cell death: parthanatos. *Ann. N. Y. Acad. Sci.* 1147, 233–241.  
471 <https://doi.org/10.1196/ANNALS.1427.014>

472 Arts, R.J.W., Joosten, L.A.B., Netea, M.G., 2018. The potential role of trained immunity  
473 in autoimmune and autoinflammatory disorders. *Front. Immunol.* 9, 339966.

- 474 <https://doi.org/10.3389/FIMMU.2018.00298/BIBTEX>
- 475 Asgharpour, F., Moghadamnia, A.A., Motallebnejad, M., Nouri, H.R., 2019. Propolis  
476 attenuates lipopolysaccharide-induced inflammatory responses through intracellular  
477 ROS and NO levels along with downregulation of IL-1 $\beta$  and IL-6 expressions in  
478 murine RAW 264.7 macrophages. *J. Food Biochem.* 43.  
479 <https://doi.org/10.1111/JFBC.12926>
- 480 Baek, S.H., Park, T., Kang, M.G., Park, D., 2020. Anti-Inflammatory Activity and ROS  
481 Regulation Effect of Sinapaldehyde in LPS-Stimulated RAW 264.7 Macrophages.  
482 *Molecules* 25. <https://doi.org/10.3390/MOLECULES25184089>
- 483 Byrne, K.A., Tuggle, C.K., Loving, C.L., 2021. Differential induction of innate memory  
484 in porcine monocytes by  $\beta$ -glucan or bacillus Calmette-Guerin. *Innate Immun.* 27,  
485 448–460. <https://doi.org/10.1177/1753425920951607>
- 486 Cárdenas-Tueme, M., Montalvo-Martínez, L., Maldonado-Ruiz, R., Camacho-Morales,  
487 A., Reséndez-Pérez, D., 2020. Neurodegenerative Susceptibility During Maternal  
488 Nutritional Programming: Are Central and Peripheral Innate Immune Training  
489 Relevant? *Front. Neurosci.* 14, 513057.  
490 <https://doi.org/10.3389/FNINS.2020.00013/BIBTEX>
- 491 David, K.K., Andrabi, S.A., Dawson, T.M., Dawson, V.L., 2009. Parthanatos, a  
492 messenger of death. *Front. Biosci. (Landmark Ed.)* 14, 1116–1128.  
493 <https://doi.org/10.2741/3297>
- 494 Elisia, I., Pae, H.B., Lam, V., Cederberg, R., Hofs, E., Krystal, G., 2018. Comparison of  
495 RAW264.7, human whole blood and PBMC assays to screen for  
496 immunomodulators. *J. Immunol. Methods* 452, 26–31.  
497 <https://doi.org/10.1016/J.JIM.2017.10.004>
- 498 Girardin, S.E., Boneca, I.G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G.,  
499 Philpott, D.J., Sansonetti, P.J., 2003. Nod2 Is a General Sensor of Peptidoglycan  
500 through Muramyl Dipeptide (MDP) Detection \*. *J. Biol. Chem.* 278, 8869–8872.  
501 <https://doi.org/10.1074/JBC.C200651200>
- 502 Gordon, S., 2003. Alternative activation of macrophages. *Nat. Rev. Immunol.* 2003 31 3,  
503 23–35. <https://doi.org/10.1038/nri978>
- 504 Guryanova, S. V., 2022. Regulation of Immune Homeostasis via Muramyl Peptides-Low  
505 Molecular Weight Bioregulators of Bacterial Origin. *Microorganisms* 10.  
506 <https://doi.org/10.3390/MICROORGANISMS10081526>
- 507 Guryanova, S. V., Khaitov, R.M., 2021. Strategies for Using Muramyl Peptides -  
508 Modulators of Innate Immunity of Bacterial Origin - in Medicine. *Front. Immunol.*  
509 12, 1339. <https://doi.org/10.3389/FIMMU.2021.607178/BIBTEX>
- 510 Guzik, T., Korbut, R., Adamek-Guzik, T., 2003. Nitric oxide and superoxide in  
511 inflammation and immune regulation. *J. Physiol. Pharmacol.*
- 512 Hamada, A., Torre, C., Drancourt, M., Ghigo, E., 2019. Trained immunity carried by non-  
513 immune cells. *Front. Microbiol.* 10, 3225.

- 514 <https://doi.org/10.3389/FMICB.2018.03225/BIBTEX>
- 515 Hartig, S. 2013. Basic image analysis and manipulation in ImageJ. *Curr Protoc Mol Biol.*  
516 14,14-15. <https://doi.org/10.1002/0471142727.mb1415s102>.
- 517 Huang, Z., Wang, J., Xu, X., Wang, H., Qiao, Y., Chu, W.C., Xu, S., Chai, L., Cottier,  
518 F., Pavelka, N., Oosting, M., Joosten, L.A.B., Netea, M., Ng, C.Y.L., Leong, K.P.,  
519 Kundu, P., Lam, K.P., Pettersson, S., Wang, Y., 2019. Antibody neutralization of  
520 microbiota-derived circulating peptidoglycan dampens inflammation and  
521 ameliorates autoimmunity. *Nat. Microbiol.* 4, 766–773.  
522 <https://doi.org/10.1038/S41564-019-0381-1>
- 523 Huynh, L., Kusnadi, A., Park, S.H., Murata, K., Park-Min, K.H., Ivashkiv, L.B., 2016.  
524 Opposing regulation of the late phase TNF response by mTORC1-IL-10 signaling  
525 and hypoxia in human macrophages. *Sci. Rep.* 6.  
526 <https://doi.org/10.1038/SREP31959>
- 527 Kelly, B., O'Neill, L.A.J., 2015. Metabolic reprogramming in macrophages and dendritic  
528 cells in innate immunity. *Cell Res.* 2015 257 25, 771–784.  
529 <https://doi.org/10.1038/cr.2015.68>
- 530 Kim, C., Wang, X.D., Yu, Y., 2020. PARP1 inhibitors trigger innate immunity via  
531 PARP1 trapping-induced DNA damage response. *Elife* 9, 1–47.  
532 <https://doi.org/10.7554/ELIFE.60637>
- 533 Leentjens, J., Bekkering, S., Joosten, L.A.B., Netea, M.G., Burgner, D.P., Riksen, N.P.,  
534 2018. Trained Innate Immunity as a Novel Mechanism Linking Infection and the  
535 Development of Atherosclerosis. *Circ. Res.* 122, 664–669.  
536 <https://doi.org/10.1161/CIRCRESAHA.117.312465>
- 537 Liu, T.F., Brown, C.M., El Gazzar, M., McPhail, L., Millet, P., Rao, A., Vachharajani,  
538 V.T., Yoza, B.K., McCall, C.E., 2012. Fueling the flame: bioenergy couples  
539 metabolism and inflammation. *J. Leukoc. Biol.* 92, 499–507.  
540 <https://doi.org/10.1189/JLB.0212078>
- 541 Liu, Y., Yan, W., Tohme, S., Chen, M., Fu, Y., Tian, D., Lotze, M., Tang, D., Tsung, A.,  
542 2015. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate  
543 tumor growth in hepatocellular carcinoma through Toll-like receptor 9. *J. Hepatol.*  
544 63, 114–121. <https://doi.org/10.1016/J.JHEP.2015.02.009>
- 545 Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-  
546 time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402–408.  
547 <https://doi.org/10.1006/METH.2001.1262>
- 548 Ma, X., Yan, W., Zheng, H., Du, Q., Zhang, L., Ban, Y., Li, N., Wei, F., 2015. Regulation  
549 of IL-10 and IL-12 production and function in macrophages and dendritic cells.  
550 *F1000Research* 4, 1–13. <https://doi.org/10.12688/F1000RESEARCH.7010.1/DOI>
- 551 MacMicking, J., Xie, Q.W., Nathan, C., 1997. Nitric oxide and macrophage function.  
552 *Annu. Rev. Immunol.* 15, 323–350.  
553 <https://doi.org/10.1146/ANNUREV.IMMUNOL.15.1.323>

- 554 Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., 2004. The  
555 chemokine system in diverse forms of macrophage activation and polarization.  
556 *Trends Immunol.* 25, 677–686. <https://doi.org/10.1016/J.IT.2004.09.015>
- 557 Martinez, F.O., Sica, A., Mantovani, A., Locati, M., 2008. Macrophage activation and  
558 polarization. *Front. Biosci.* 13, 453–461. <https://doi.org/10.2741/2692>
- 559 Mishra, S., Arsh, A.M., Rathore, J.S., 2022. Trained innate immunity and diseases: Bane  
560 with the boon. *Clin. Immunol. Commun.* 2, 118–129.  
561 <https://doi.org/10.1016/J.CLICOM.2022.08.004>
- 562 Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B., Chavakis, T., Divangahi, M., Fuchs,  
563 E., Joosten, L.A.B., van der Meer, J.W.M., Mhlanga, M.M., Mulder, W.J.M.,  
564 Riksen, N.P., Schlitzer, A., Schultze, J.L., Stabell Benn, C., Sun, J.C., Xavier, R.J.,  
565 Latz, E., 2020. Defining trained immunity and its role in health and disease. *Nat.*  
566 *Rev. Immunol.* 20, 375–388. <https://doi.org/10.1038/s41577-020-0285-6>
- 567 Netea, M.G., Quintin, J., Van Der Meer, J.W.M., 2011. Trained immunity: a memory for  
568 innate host defense. *Cell Host Microbe* 9, 355–361.  
569 <https://doi.org/10.1016/J.CHOM.2011.04.006>
- 570 Ogawa, C., Liu, Y. and Kobayashi, K., 2011. Muramyl dipeptide and its derivatives:  
571 peptide adjuvant in immunological disorders and cancer therapy. *Curr Bioact*  
572 *Compd.* 7(3), 180–197. <https://doi.org/10.2174/157340711796817913>
- 573 Park, S.H., Park-Min, K.H., Chen, J., Hu, X., Ivashkiv, L.B., 2011. Tumor necrosis factor  
574 induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. *Nat.*  
575 *Immunol.* 12, 607–615. <https://doi.org/10.1038/NI.2043>
- 576 Pashenkov, M. V., Murugina, N.E., Budikhina, A.S., Pinegin, B. V., 2019. Synergistic  
577 interactions between NOD receptors and TLRs: Mechanisms and clinical  
578 implications. *J. Leukoc. Biol.* 105, 669–680. <https://doi.org/10.1002/JLB.2RU0718-290R>
- 580 Quintin, J., Cheng, S.C., van der Meer, J.W.M., Netea, M.G., 2014. Innate immune  
581 memory: towards a better understanding of host defense mechanisms. *Curr. Opin.*  
582 *Immunol.* 29, 1–7. <https://doi.org/10.1016/J.COI.2014.02.006>
- 583 Regdon, Z., Robaszkiewicz, A., Kovács, K., Rygielska, Ż., Hegedűs, C., Bodoor, K.,  
584 Szabó, É., Virág, L., 2019. LPS protects macrophages from AIF-independent  
585 parthanatos by downregulation of PARP1 expression, induction of SOD2  
586 expression, and a metabolic shift to aerobic glycolysis. *Free Radic. Biol. Med.* 131,  
587 184–196. <https://doi.org/10.1016/J.FREERADBIOMED.2018.11.034>
- 588 Robinson, N., Ganesan, R., Hegedűs, C., Kovács, K., Kufer, T.A., Virág, L., 2019.  
589 Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis,  
590 and parthanatos. *Redox Biol.* 26. <https://doi.org/10.1016/J.REDOX.2019.101239>
- 591 Rodríguez-Prados, J.-C., Través, P.G., Cuenca, J., Rico, D., Aragonés, J., Martín-Sanz,  
592 P., Cascante, M., Boscá, L., 2010. Substrate fate in activated macrophages: a  
593 comparison between innate, classic, and alternative activation. *J. Immunol.* 185,  
594 605–614. <https://doi.org/10.4049/JIMMUNOL.0901698>



- 595 Swindall, A.F., Stanley, J.A., Yang, E.S., 2013. PARP-1: Friend or Foe of DNA Damage  
596 and Repair in Tumorigenesis? *Cancers (Basel)*. 5, 943–958.  
597 <https://doi.org/10.3390/CANCERS5030943>
- 598 Taciak, B., Białasek, M., Braniewska, A., Sas, Z., Sawicka, P., Kiraga, Ł., Rygiel, T.,  
599 Król, M., 2018. Evaluation of phenotypic and functional stability of RAW 264.7 cell  
600 line through serial passages. *PLoS One* 13.  
601 <https://doi.org/10.1371/JOURNAL.PONE.0198943>
- 602 Underhill, D.M., 2007. Collaboration between the innate immune receptors dectin-1,  
603 TLRs, and Nods. *Immunol. Rev.* 219, 75–87. <https://doi.org/10.1111/J.1600-065X.2007.00548.X>
- 605 Van Ginderachter, J.A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S.,  
606 Beschin, A., Raes, G., De Baetselier, P., 2006. Classical and alternative activation  
607 of mononuclear phagocytes: picking the best of both worlds for tumor promotion.  
608 *Immunobiology* 211, 487–501. <https://doi.org/10.1016/J.IMBIO.2006.06.002>
- 609 Wang, L. xun, Zhang, S. xi, Wu, H. juan, Rong, X. lu, Guo, J., 2019. M2b macrophage  
610 polarization and its roles in diseases. *J. Leukoc. Biol.* 106, 345–358.  
611 <https://doi.org/10.1002/JLB.3RU1018-378RR>
- 612 Wang, Y., Li, N., Zhang, X., Horng, T., 2021. Mitochondrial metabolism regulates  
613 macrophage biology. *J. Biol. Chem.* 297, 100904.  
614 <https://doi.org/10.1016/j.jbc.2021.100904>
- 615 Wei, J., Wang, B., Chen, Y., Wang, Q., Ahmed, A.F., Zhang, Y., Kang, W., 2022. The  
616 Immunomodulatory Effects of Active Ingredients From *Nigella sativa* in RAW264.7  
617 Cells Through NF- $\kappa$ B/MAPK Signaling Pathways. *Front. Nutr.* 9.  
618 <https://doi.org/10.3389/FNUT.2022.899797>
- 619 Xue, Q., Liu, X., Chen, C., Zhang, X., Xie, P., Liu, Y., Zhou, S., Tang, J., 2021. Erlotinib  
620 protests against LPS-induced parthanatos through inhibiting macrophage surface  
621 TLR4 expression. *Cell death Discov.* 7. <https://doi.org/10.1038/S41420-021-00571-4>  
622 4
- 623 Yu, X., Wu, B., Lin, Y., Xiong, H.-Y., Xie, C., Liu, C., Li, Z., Tu, Z., 2016.  
624 Overexpression of IL-12 reverses the phenotype and function of M2 macrophages  
625 to M1 macrophages.
- 626
- 627
- 628 **6 Acknowledgments:** Dr. Ivana Soria and Dr. Fernando Delgado for technical support  
629 and Dr. Mariano Perez-Filgueira for critical reading of the manuscript.  
630
- 631 **7 Funding:** This work was funded by the National Institute of Livestock and  
632 Agriculture Technologies (INTA). FCM is researcher of INTA; MCM, SSM and  
633 AVC are researchers from the National Council for Technical Research (CONICET).
- 634 **8 Author contributions:** FCM: conceptualization, methodology, formal analysis and  
635 visualization, writing original draft; MCM: methodology, data curation, review and

636 editing; SSM: data curation, validation, review and editing; CPR: methodology,  
637 review and editing; AVC: Funding acquisition, Visualization, review and editing.

638

639 **Declaration of interests**

640

641 The authors declare that they have no known competing financial interests or personal  
642 relationships that could have appeared to influence the work reported in this paper.

643

644 The authors declare the following financial interests/personal relationships which may be  
645 considered as potential competing interests:

646

647

648

649

650

651

652